Generic Medicine Info
May be taken with or without food.
Pre-existing 2nd- or 3rd-degree AV block w/o pacemaker, right bundle branch block associated w/ left hemiblock w/o pacemaker, cardiogenic shock, heart failure, history of MI, known Brugada syndrome.
Special Precautions
Patient w/ pacemakers, atrial fibrillation following cardiac surgery, atrial flutter, and structural heart disease. Renal (CrCl ≤35 mL/min) and significant hepatic impairment. Elderly. Childn. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and visual disturbances, if affected, do not drive or operate machinery. Monitoring ParametersMonitor ECG, BP, plasma levels, and resp function.
Adverse Reactions
Pro-arrhythmic effects, dizziness, visual disturbances, lightheadedness, giddiness, nausea, vomiting, headache, tremor, peripheral neuropathy, ataxia, paraesthesia, hypaesthesia, hyperhidrosis, syncope, tremor, vertigo, flushing, somnolence, tinnitus, increased sweating, depression, anxiety, insomnia, photosensitivity, and mild blood cells reduction. Rarely, hallucinations, amnesia, confusion, depression, dyskinesia, convulsion, urticaria, chest pain, elevated liver enzyme.
Potentially Fatal: Ventricular tachyarrhythmia, MI.
Drug Interactions
Increased incidence of cardiac arrhythmias w/ other antiarrhythmics or arrhythmogenic drugs. Additive negative inotropic effects w/ Class II antiarrhythmics. Increased plasma conc w/ amiodarone, cimetidine quinidine, and ritonavir. Hypokalaemia may result w/ diuretics, corticosteroids, and laxatives.
CIMS Class
ATC Classification
C01BC04 - flecainide ; Belongs to class Ic antiarrhythmics.
Disclaimer: This information is independently developed by CIMS based on flecainide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in